Company: ANIX
Filing Date: 2025-01-10
Form Type: S-8
Source: 0001493152-25-001798
Chunk: 36

Company: Anixa Biosciences Inc
Filing Date: 2025-01-10
Form: S-8
Chunk 36
---
 infringe on intellectual property of the licensor that is not subject   
 to the licensing agreement;                                                                                                              |
| ● | the                                                                                                                                      
 sublicensing of patent and other rights under the licensing agreement and our collaborative development relationships;                   |
| ● | our                                                                                                                                      
 diligence obligations under the license agreement and what activities satisfy those diligence obligations;                               |
| ● | the                                                                                                                                      
 inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors 
 and us and our partners; and                                                                                                             |
| ● | the                                                                                                                                      
 priority of invention of patented technology.                                                                                            |

If we do not prevail in such disputes, we may lose any of such license agreements.

In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.

Our failure to maintain such licenses could have a material adverse effect on our business, financial condition and results of operations. Any of these licenses could be terminated, such as if either party fails to abide by the terms of the license, or if the licensor fails to prevent infringement by third parties or if the licensed patents or other rights are found to be invalid or unenforceable. Absent the license agreements, we may infringe patents subject to those agreements, and if the license agreements are terminated, we may be subject to litigation by the licensor. Litigation could result in substantial costs and be a distraction to management. If we do not prevail, we may be required to pay damages, including treble damages, attorneys’ fees, costs and expenses, royalties or, be enjoined from selling our products, which could adversely affect our ability to offer products, our ability to continue operations and our financial condition.

| 22 |

If our efforts to protect the proprietary nature of our technologies are not adequate, we may not be